Cartesian Therapeutics, INC Form 4 insider transactions

Elizabeth Hoge, a director at Cartesian Therapeutics, Inc., reported a conversion of Series A Preferred Stock into common stock and related beneficial ownership changes.

Director Murat Kalayoglu reported a conversion of preferred stock to common stock and a disposition of common stock in Cartesian Therapeutics, Inc. on April 2, 2026.

Michael Singer, a Director at Cartesian Therapeutics, Inc., reported gifting 6,555 shares of common stock on March 13, 2026.

Cartesian Therapeutics' President and CEO, Carsten Brunn, sold 23,766 shares of common stock to cover tax obligations and broker fees.

Cartesian Therapeutics' Chief Medical Officer, Milos Miljkovic, sold 3,573 shares of common stock to cover tax obligations and broker fees.

Cartesian Therapeutics CFO Blaine Davis sold 10,591 shares of common stock to cover tax obligations and broker fees related to restricted stock unit vesting.

Cartesian Therapeutics Director Timothy C. Barabe acquired 2,600 restricted stock units and 7,800 stock options, signaling increased insider confidence.

Cartesian Therapeutics' Chief Operations Officer, Emily English, acquired 24,000 restricted stock units and 71,000 stock options, signaling increased insider ownership.

Cartesian Therapeutics Director Nishan M. DeSilva acquired 2,600 Restricted Stock Units and 7,800 stock options on January 2, 2026.

Cartesian Therapeutics' President and CEO, Carsten Brunn, acquired 143,200 shares of common stock and 415,700 stock options, signaling increased insider ownership and long-term incentive alignment.

Cartesian Therapeutics Director Kemal Malik acquired 2,600 restricted stock units and 7,800 stock options, signaling increased insider ownership and potential confidence in the company's future.

Cartesian Therapeutics' Chief Medical Officer, Milos Miljkovic, was granted 27,000 restricted stock units and options for 77,000 shares of common stock.

Cartesian Therapeutics Director Patrick J. Zenner acquired 2,600 restricted stock units and 7,800 stock options on January 2, 2026, signaling increased insider ownership.

Cartesian Therapeutics' Chief Accounting Officer, June Ann Seymour, was granted 6,500 Restricted Stock Units and options to purchase 19,000 shares of common stock.

Cartesian Therapeutics' CFO, Blaine Davis, acquired 37,000 shares of common stock and 109,000 employee stock options on January 2, 2026.

Cartesian Therapeutics Director Michael Singer reported acquiring 2,600 restricted stock units and 7,800 stock options, increasing his beneficial ownership.

Cartesian Therapeutics Director Timothy A. Springer acquired 2,600 common stock units and 7,800 stock options, increasing his beneficial ownership.

Cartesian Therapeutics Director and 10% owner Murat Kalayoglu acquired 2,600 Restricted Stock Units and 7,800 stock options on January 2, 2026.

Cartesian Therapeutics' Chief Operations Officer, Emily English, exercised 7,500 stock options at $3.30 per share, increasing her direct common stock holdings.

Cartesian Therapeutics, Inc. granted 5,800 Restricted Stock Units and 17,200 stock options to Director Adrian Ion Bot, with vesting scheduled through December 2028.

Cartesian Therapeutics Director Timothy C. Barabe acquired 30,000 shares of common stock at a weighted average price of $6.8599.

Cartesian Therapeutics' Chief Operations Officer, Emily English, exercised 7,500 stock options at $3.30 per share, increasing her direct common stock holdings to 62,726 shares.

Michael Singer, a Director at Cartesian Therapeutics, Inc., reported gifting 20,000 shares of common stock on November 18, 2025.

Cartesian Therapeutics' Chief Accounting Officer, June Ann Seymour, was granted 50,000 employee stock options with an exercise price of $8.85.

Emily English, Chief Operations Officer of Cartesian Therapeutics, exercised stock options to acquire 7,500 shares of common stock at $3.3 per share on May 12, 2025.

Emily English, Chief Operations Officer of Cartesian Therapeutics, exercised stock options on April 15, 2025, acquiring 7,500 shares of common stock.

Director and 10% owner Timothy A. Springer reports purchasing shares of Cartesian Therapeutics (RNAC) between April 9th and April 11th, 2025, increasing both direct and indirect holdings.

Director and 10% owner Timothy A. Springer has increased his holdings in Cartesian Therapeutics, Inc. (RNAC) through a series of open market purchases.

Director and 10% owner Timothy A. Springer reports purchasing additional shares of Cartesian Therapeutics, Inc. (RNAC) common stock.

Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, exercised stock options to acquire 9,000 shares of common stock at $3.23 per share.